Umpqua Bank Increases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Umpqua Bank boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 8.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,555 shares of the company's stock after buying an additional 1,688 shares during the quarter. Johnson & Johnson makes up 1.0% of Umpqua Bank's portfolio, making the stock its 23rd largest position. Umpqua Bank's holdings in Johnson & Johnson were worth $2,975,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in JNJ. Swedbank AB increased its holdings in Johnson & Johnson by 5.3% during the third quarter. Swedbank AB now owns 2,215,108 shares of the company's stock valued at $358,980,000 after buying an additional 111,570 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Johnson & Johnson by 10.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock valued at $562,723,000 after acquiring an additional 329,473 shares during the period. United Bank raised its position in shares of Johnson & Johnson by 5.6% in the 3rd quarter. United Bank now owns 3,788 shares of the company's stock worth $614,000 after acquiring an additional 202 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth $5,883,000. Finally, Landscape Capital Management L.L.C. bought a new stake in Johnson & Johnson during the third quarter valued at about $365,000. 69.55% of the stock is currently owned by institutional investors.

Remove Ads

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on JNJ shares. Citigroup decreased their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research note on Monday, March 10th. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a report on Tuesday, January 28th. Finally, Raymond James lowered their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $171.33.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded down $2.15 during midday trading on Tuesday, reaching $161.14. 7,455,754 shares of the company's stock traded hands, compared to its average volume of 7,086,516. The company has a fifty day simple moving average of $157.70 and a two-hundred day simple moving average of $156.14. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a market cap of $388.32 billion, a P/E ratio of 24.23, a PEG ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter last year, the business earned $2.29 earnings per share. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were issued a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.08%. Johnson & Johnson's payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.